ASSISTANCE PUBLIQUE HOPITAUX DE PARIS

VolitionRx's Sepsis Biomarker Selected for €6.3 Million French National Healthcare Initiative

- VolitionRx's Nu.Q NETs H3.1 assay has been selected as the exclusive biomarker for DETECSEPS, a French government-funded initiative evaluating early sepsis detection methods with €6.3 million in funding. - The biomarker shows strong correlation with disease severity and provides excellent prognostic utility for outcomes including organ failure and mortality, with prognostic power exceeding established severity scores like APACHE II and SOFA. - The assay can deliver results within one hour using automated analyzers, potentially transforming emergency care pathways for patients with infection and sepsis risk. - The initiative aims to address sepsis's significant global burden of approximately 166 million cases annually resulting in 21.4 million deaths, representing a multi-billion dollar market opportunity.